- Home
- ARCT vs PRTC Comparison
ARCT vs PRTC Comparison
Compare ARCT & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- PRTC
- Stock Information
- Founded
- ARCT 2013
- PRTC 2015
- Country
- ARCT United States
- PRTC United States
- Employees
- ARCT N/A
- PRTC N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- PRTC Health Care
- Exchange
- ARCT Nasdaq
- PRTC Nasdaq
- Market Cap
- ARCT 373.7M
- PRTC 413.5M
- IPO Year
- ARCT N/A
- PRTC N/A
- Fundamental
- Price
- ARCT $14.94
- PRTC $19.07
- Analyst Decision
- ARCT Strong Buy
- PRTC Buy
- Analyst Count
- ARCT 8
- PRTC 1
- Target Price
- ARCT $52.83
- PRTC $45.00
- AVG Volume (30 Days)
- ARCT 443.2K
- PRTC 3.4K
- Earning Date
- ARCT 08-04-2025
- PRTC 08-27-2025
- Dividend Yield
- ARCT N/A
- PRTC N/A
- EPS Growth
- ARCT N/A
- PRTC N/A
- EPS
- ARCT N/A
- PRTC 0.21
- Revenue
- ARCT $143,680,000.00
- PRTC $4,828,000.00
- Revenue This Year
- ARCT N/A
- PRTC $35.98
- Revenue Next Year
- ARCT $34.08
- PRTC $115.38
- P/E Ratio
- ARCT N/A
- PRTC $8.64
- Revenue Growth
- ARCT 15.38
- PRTC 44.98
- 52 Week Low
- ARCT $8.04
- PRTC $13.30
- 52 Week High
- ARCT $25.88
- PRTC $25.00
- Technical
- Relative Strength Index (RSI)
- ARCT 60.54
- PRTC 57.26
- Support Level
- ARCT $12.75
- PRTC $18.16
- Resistance Level
- ARCT $15.83
- PRTC $19.60
- Average True Range (ATR)
- ARCT 0.86
- PRTC 0.43
- MACD
- ARCT 0.12
- PRTC 0.10
- Stochastic Oscillator
- ARCT 71.10
- PRTC 69.77
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.